ACRV
ACRV
NASDAQ · Biotechnology

Acrivon Therapeutics Inc

$1.67
+0.07 (+4.38%)
As of Feb 8, 2:18 PM ET ·
Analyst Consensus
Strong Buy
15
Analysts
High
Coverage
Buy 13 87%
Hold 2 13%
Sell 0 0%
Price Target
Analyst Price Target +2,451.5% upside
Low Target $22.54
Average Target $42.61
High Target $49.20
Current Price $1.67
Current
$1.67
Target
$42.61
$22.54 $42.61 avg $49.20
Scenario Analysis
Bear Case
$22.54
1,249.7%
Low target
Base Case
$42.61
+2,451.5%
Avg target
Bull Case
$49.20
+2,846.1%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$41.09
-95.9% from high
52-Week Low
$27.16
+-93.9% from low
Target vs 52W High
$42.61
+3.7% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%